Selected article for: "incubation time and long time"
Author: Yan, Yan-yan; Zhou, Wen-min; Wang, Yu-qing; Guo, Qiao-ru; Zhao, Fu-xi; Zhu, Zhuang-yan; Xing, Yan-xia; Zhang, Hai-yan; Aljofan, Mohamad; Jarrahi, Alireza Mosavi; Makabel, Bolat; Zhang, Jian-ye
Title: The Potential Role of Extracellular Vesicles in COVID-19 Treatment: Opportunity and Challenge
  • Cord-id: simz08sb
  • Document date: 2021_7_21
    • ID: simz08sb
    Snippet: SARS-CoV-2 infection has become an urgent public health concern worldwide, severely affecting our society and economy due to the long incubation time and high prevalence. People spare no effort on the rapid development of vaccine and treatment all over the world. Amongst the numerous ways of tackling this pandemic, some approaches using extracellular vesicles (EVs) are emerging. In this review, we summarize current prevalence and pathogenesis of COVID-19, involving the combination of SARS-CoV-2
    Document: SARS-CoV-2 infection has become an urgent public health concern worldwide, severely affecting our society and economy due to the long incubation time and high prevalence. People spare no effort on the rapid development of vaccine and treatment all over the world. Amongst the numerous ways of tackling this pandemic, some approaches using extracellular vesicles (EVs) are emerging. In this review, we summarize current prevalence and pathogenesis of COVID-19, involving the combination of SARS-CoV-2 and virus receptor ACE2, endothelial dysfunction and micro thrombosis, together with cytokine storm. We also discuss the ongoing EVs-based strategies for the treatment of COVID-19, including mesenchymal stem cell (MSC)-EVs, drug-EVs, vaccine-EVs, platelet-EVs, and others. This manuscript provides the foundation for the development of targeted drugs and vaccines for SARS-CoV-2 infections.

    Search related documents:
    Co phrase search for related documents
    • ace activity and acute lung injury lead: 1
    • ace activity and acute phase: 1
    • ace homolog and adipose tissue: 1
    • acid content and acute phase: 1
    • acid content and adipose tissue: 1
    • activate platelet and adenoviral vector: 1, 2
    • acute cardiac injury and administration time: 1
    • acute lung injury and adenoviral vector: 1
    • acute lung injury and adipose tissue: 1, 2
    • acute lung injury and administration time: 1, 2, 3, 4
    • acute lung injury and lncrnas mrnas mirnas: 1
    • acute lung injury lead and lncrnas mrnas mirnas: 1
    • acute phase and adipose tissue: 1
    • acute phase and administration time: 1, 2, 3